Astellas in Pact for Cell Therapy
By

By
Astellas Pharma’s Astellas Institute for Regenerative Medicine (AIRM) and Universal Cells,a Seattle-based biotechnology company, have signed an agreement to research, develop, and commercialize a cell therapy for an undisclosed indication.…

GSK Partners in Combinatorial Stem-Cell Technology
By

By
GlaxoSmithKline (GSK) and Plasticell, a biotechnology company using combinatorial cell-culture technologies for optimization of cell and gene-therapy manufacturing, have signed a pact to optimize induced pluripotent stem cells (iPSCs) differentiation…

AbbVie, Harpoon Therapeutics in Immuno-Oncology Pact
By

By
AbbVie and Harpoon Therapeutics, a biotechnology company developing T-cell recruiting biologic therapies, have formed an immuno-oncology research collaboration. The goal of the collaboration is to incorporate Harpoon’s tri-specific T-cell activating…

Cambrex Adds to Large-Scale Manufacturing Capacity
By

By
Cambrex, a contract manufacturer of small-molecule active pharmaceutical ingredients (APIs), has completed an expansion of large-scale production capacity at its plant in Charles City, Iowa. The investment included the installation…

Lilly To Invest $72 Million in Insulin Manufacturing
By

By
Eli Lilly and Company plans to invest $72 million in an insulin-manufacturing project at one of its facilities in Indianapolis, Indiana. The project is part of the company’s $850-million investment…

PhRMA, NIH Form Immuno-Oncology Initiative
By

By
The Pharmaceutical Research and Manufacturers of America (PhRMA), an industry trade group of innovator-research-based pharmaceutical companies, and nine of its member companies and the US National Institutes of Health (NIH)…

US Senate Holds Second Hearing on Drug Pricing
By

By
The US Senate Health, Education, Labor and Pensions (HELP) Committee held a second hearing in a series of hearings to address prescription-drug costs. Among the organizations testifying were the Pharmaceutical…

Novartis to Close Solid-Dosage Plant in Colorado
By

By
Novartis plans to close an oral solid-dosage manufacturing facility in Broomfield, Colorado that is owned by its generics arm, Sandoz. Approximately 450 jobs will be affected as a result of…

Pfizer Recalls Select Batches of Antibiotic in Australia
By

By
Pfizer has issued a voluntary Class I recall in Australia of 10 batches of its antibiotic, gentamicin Injection BP 80 mg in 2-mL Steriluer ampoules in packs of 10 and…

Lilly in Cancer Vaccine Pact Worth up to $1.7 Billion
By

By
Eli Lilly and Company and CureVac, a Tübingen, Germany-headquartered clinical-stage biopharmaceutical company focused on mRNA (messenger ribonucleic acid)-based drug development, have partnered to develop cancer vaccine products in a deal…